TY - JOUR
T1 - Global coronal decompensation and adult spinal deformity surgery
T2 - comparison of upper-thoracic versus lower-thoracic proximal fixation for long fusions
AU - The International Spine Study Group (ISSG)
AU - Buell, Thomas J.
AU - Shaffrey, Christopher I.
AU - Kim, Han Jo
AU - Klineberg, Eric O.
AU - Lafage, Virginie
AU - Lafage, Renaud
AU - Protopsaltis, Themistocles S.
AU - Passias, Peter G.
AU - Mundis, Gregory M.
AU - Eastlack, Robert K.
AU - Deviren, Vedat
AU - Kelly, Michael P.
AU - Daniels, Alan H.
AU - Gum, Jeffrey L.
AU - Soroceanu, Alex
AU - Hamilton, D. Kojo
AU - Gupta, Munish C.
AU - Burton, Douglas C.
AU - Hostin, Richard A.
AU - Kebaish, Khaled M.
AU - Hart, Robert A.
AU - Schwab, Frank J.
AU - Bess, Shay
AU - Ames, Christopher P.
AU - Smith, Justin S.
N1 - Funding Information:
The International Spine Study Group (ISSG) is funded through research grants from DePuy Synthes. Dr. Shaffrey is a consultant for Medtronic, NuVasive, and SI Bone; owns stock in NuVasive; holds patents with Medtronic, NuVasive, and Zimmer Biomet; and receives royalties from NuVasive. Dr. Klineberg is a consultant for DePuy Synthes, Stryker, and Medicrea/Medtronic; receives honoraria from AO Spine; and has a fellowship grant from AO Spine. Dr. Lafage is a consultant for Globus Medical; receives royalties from NuVasive; receives honoraria from The Permanente Group, DePuy Synthes, Implanet, and J&J; and owns stock in Nemaris Inc. Mr. Lafage owns stock in Nemaris. Dr. Protopsaltis is a consultant for Globus, Stryker K2M, NuVasive, Medicrea, and Medtronic; receives royalties from Altus; and owns stock options in SpineAlign and Torus
Funding Information:
Royal Biologics, and Medicrea; is on the speakers bureau of Zimmer and Globus Medical; and receives clinical or research support for the study described from Allosource and cSRS. Dr. Mundis is a consultant for NuVasive, K2M/Stryker, Viseon, SeaSpine, and Carlsmed; owns stock in NuVasive, Carlsmed, Viseon, SeaSpine, and Alphatec; receives royalties from NuVasive and K2M/Stryker; and holds patents with K2M/Stryker. Dr. Eastlack owns stock in Spine Innovation, Alphatec, SeaSpine, and NuVasive; is a consultant for NuVasive, SeaSpine, SI Bone, Stryker, Medtronic, and Spinal Elements; holds patients with Spine Innovation, Globus, and Stryker; is on the speakers bureau of Radius; receives royalties from Globus, SeaSpine, NuVasive, and SI Bone; and receives non–study-related clinical or research support from NuVasive, SeaSpine, and Medtronic. Dr. Deviren is a consultant for NuVasive, Biomet, SeaSpine, Medicrea, and Alphatec; receives royalties from NuVasive; receives institutional fellowship support NuVasive; and owns stock in Omega. Dr. Kelly receives non–study related clinical or research support from DePuy/Synthes Spine and receives honoraria from The Journal of Bone and Joint Surgery. Dr. Daniels is a consultant for Spineart, Stryker, Medtronic, Medicrea, EOS, and Orthofix and receives royalties from Spineart, Medicrea, and Springer. Dr. Gum is an employee of Norton Healthcare; is a consultant for Medtronic, Acuity, K2M/Stryker, NuVasive, and Mazor; is on the speakers bureau of DePuy; receives royalties from Acuity and NuVasive; receives honoraria from Pacira Pharmaceuticals, Baxter, Broadwater, and NASS; receives clinical or research support for the study described from Integra, Intellirod Spine Inc, Pfizer, ISSG, NuVasive, and Norton Healthcare; owns stock in Cingulate Therapeutics; holds patents with Medtronic; and serves on the advisory/editorial boards of K2M/Stryker, Medtronic, and National Spine Health. Dr. Gupta owns stock in J&J and P&G; receives royalties from Innomed, Globus, and DePuy; is a consultant for DePuy, Medtronic, and Globus; receives honoraria from AO Spine; and receives travel reimbursements from DePuy, Medtronic, SRS, AO Spine, Medicrea, Mizuho, and Alphatec. Dr. Burton owns stock in Progenerative Medical; receives royalties from DePuy; and receives clinical or research support for the study described from DePuy. Dr. Schwab is a consultant for ZimmerBiomet, MSD, and K2M; receives royalties from ZimmerBiomet, MSD, and Medicrea; and serves on the executive committee of ISSG. Dr. Bess is a consultant for K2 Stryker and Mirus; owns stock in Progenerative Medical and Carlsmed; holds patents with K2 Stryker and NuVasive; receives clinical or research support for the study described from ISSGF, K2 Stryker, NuVasive, and DePuy Synthes; receives non–study-related clinical or research support from ISSGF, NuVasive, Medtronic, DePuy Synthes, K2 Stryker, SI Bone, and SeaSpine; and receives royalties from K2 Stryker and NuVasive. Dr. Ames is an employee of UCSF; receives royalties from Stryker, Biomet Zimmer Spine, DePuy Synthes, NuVasive, Next Orthosurgical, K2M, and Medicrea; owns stock in DePuy Synthes; is a consultant for Medtronic, Medicrea, K2M, and Titan Spine; receives research support from Titan Spine, DePuy Synthes, and ISSG; serves on the editorial board of Operative Neurosurgery; receives grant funding from SRS; serves on the executive committee of ISSG; and serves as the director of Global Spinal Analytics. Dr. Smith is a consultant for Cerapedics, Carlsmed, Stryker, DePuy Synthes, NuVasive, and Zimmer Biomet; receives royalties from Zimmer Biomet, NuVasive, and Thieme; receives clinical or research support for the study described from DePuy Synthes and ISSGF; receives non–study-related clinical or research support from DePuy Synthes, ISSGF, NuVasive, and AO Spine; owns stock in NuVasive and Alphatec; and receives fellowship funding from AO Spine.
Publisher Copyright:
© AANS 2021, except where prohibited by US copyright law.
PY - 2021/12
Y1 - 2021/12
N2 - OBJECTIVE Deterioration of global coronal alignment (GCA) may be associated with worse outcomes after adult spinal deformity (ASD) surgery. The impact of fusion length and upper instrumented vertebra (UIV) selection on patients with this complication is unclear. The authors’ objective was to compare outcomes between long sacropelvic fusion with upper-thoracic (UT) UIV and those with lower-thoracic (LT) UIV in patients with worsening GCA ≥ 1 cm. METHODS This was a retrospective analysis of a prospective multicenter database of consecutive ASD patients. Index operations involved instrumented fusion from sacropelvis to thoracic spine. Global coronal deterioration was defined as worsening GCA ≥ 1 cm from preoperation to 2-year follow-up. RESULTS Of 875 potentially eligible patients, 560 (64%) had complete 2-year follow-up data, of which 144 (25.7%) demonstrated worse GCA at 2-year postoperative follow-up (35.4% of UT patients vs 64.6% of LT patients). At baseline, UT patients were younger (61.6 ± 9.9 vs 64.5 ± 8.6 years, p = 0.008), a greater percentage of UT patients had osteoporosis (35.3% vs 16.1%, p = 0.009), and UT patients had worse scoliosis (51.9° ± 22.5° vs 32.5° ± 16.3°, p < 0.001). Index operations were comparable, except UT patients had longer fusions (16.4 ± 0.9 vs 9.7 ± 1.2 levels, p < 0.001) and operative duration (8.6 ± 3.2 vs 7.6 ± 3.0 hours, p = 0.023). At 2-year follow-up, global coronal deterioration averaged 2.7 ± 1.4 cm (1.9 to 4.6 cm, p < 0.001), scoliosis improved (39.3° ± 20.8° to 18.0° ± 14.8°, p < 0.001), and sagittal spinopelvic alignment improved significantly in all patients. UT patients maintained smaller positive C7 sagittal vertical axis (2.7 ± 5.7 vs 4.7 ± 5.7 cm, p = 0.014). Postoperative 2-year health-related quality of life (HRQL) significantly improved from baseline for all patients. HRQL comparisons demonstrated that UT patients had worse Scoliosis Research Society–22r (SRS-22r) Activity (3.2 ± 1.0 vs 3.6 ± 0.8, p = 0.040) and SRS-22r Satisfaction (3.9 ± 1.1 vs 4.3 ± 0.8, p = 0.021) scores. Also, fewer UT patients improved by ≥ 1 minimal clinically important difference in numerical rating scale scores for leg pain (41.3% vs 62.7%, p = 0.020). Comparable percentages of UT and LT patients had complications (208 total, including 53 reoperations, 77 major complications, and 78 minor complications), but the percentage of reoperated patients was higher among UT patients (35.3% vs 18.3%, p = 0.023). UT patients had higher reoperation rates of rod fracture (13.7% vs 2.2%, p = 0.006) and pseudarthrosis (7.8% vs 1.1%, p = 0.006) but not proximal junctional kyphosis (9.8% vs 8.6%, p = 0.810). CONCLUSIONS In ASD patients with worse 2-year GCA after long sacropelvic fusion, UT UIV was associated with worse 2-year HRQL compared with LT UIV. This may suggest that residual global coronal malalignment is clinically less tolerated in ASD patients with longer fusion to the proximal thoracic spine. These results may inform operative planning and improve patient counseling.
AB - OBJECTIVE Deterioration of global coronal alignment (GCA) may be associated with worse outcomes after adult spinal deformity (ASD) surgery. The impact of fusion length and upper instrumented vertebra (UIV) selection on patients with this complication is unclear. The authors’ objective was to compare outcomes between long sacropelvic fusion with upper-thoracic (UT) UIV and those with lower-thoracic (LT) UIV in patients with worsening GCA ≥ 1 cm. METHODS This was a retrospective analysis of a prospective multicenter database of consecutive ASD patients. Index operations involved instrumented fusion from sacropelvis to thoracic spine. Global coronal deterioration was defined as worsening GCA ≥ 1 cm from preoperation to 2-year follow-up. RESULTS Of 875 potentially eligible patients, 560 (64%) had complete 2-year follow-up data, of which 144 (25.7%) demonstrated worse GCA at 2-year postoperative follow-up (35.4% of UT patients vs 64.6% of LT patients). At baseline, UT patients were younger (61.6 ± 9.9 vs 64.5 ± 8.6 years, p = 0.008), a greater percentage of UT patients had osteoporosis (35.3% vs 16.1%, p = 0.009), and UT patients had worse scoliosis (51.9° ± 22.5° vs 32.5° ± 16.3°, p < 0.001). Index operations were comparable, except UT patients had longer fusions (16.4 ± 0.9 vs 9.7 ± 1.2 levels, p < 0.001) and operative duration (8.6 ± 3.2 vs 7.6 ± 3.0 hours, p = 0.023). At 2-year follow-up, global coronal deterioration averaged 2.7 ± 1.4 cm (1.9 to 4.6 cm, p < 0.001), scoliosis improved (39.3° ± 20.8° to 18.0° ± 14.8°, p < 0.001), and sagittal spinopelvic alignment improved significantly in all patients. UT patients maintained smaller positive C7 sagittal vertical axis (2.7 ± 5.7 vs 4.7 ± 5.7 cm, p = 0.014). Postoperative 2-year health-related quality of life (HRQL) significantly improved from baseline for all patients. HRQL comparisons demonstrated that UT patients had worse Scoliosis Research Society–22r (SRS-22r) Activity (3.2 ± 1.0 vs 3.6 ± 0.8, p = 0.040) and SRS-22r Satisfaction (3.9 ± 1.1 vs 4.3 ± 0.8, p = 0.021) scores. Also, fewer UT patients improved by ≥ 1 minimal clinically important difference in numerical rating scale scores for leg pain (41.3% vs 62.7%, p = 0.020). Comparable percentages of UT and LT patients had complications (208 total, including 53 reoperations, 77 major complications, and 78 minor complications), but the percentage of reoperated patients was higher among UT patients (35.3% vs 18.3%, p = 0.023). UT patients had higher reoperation rates of rod fracture (13.7% vs 2.2%, p = 0.006) and pseudarthrosis (7.8% vs 1.1%, p = 0.006) but not proximal junctional kyphosis (9.8% vs 8.6%, p = 0.810). CONCLUSIONS In ASD patients with worse 2-year GCA after long sacropelvic fusion, UT UIV was associated with worse 2-year HRQL compared with LT UIV. This may suggest that residual global coronal malalignment is clinically less tolerated in ASD patients with longer fusion to the proximal thoracic spine. These results may inform operative planning and improve patient counseling.
KW - Adult spinal deformity
KW - HRQL
KW - complications
KW - coronal imbalance/malalignment
KW - global coronal alignment
KW - health-related quality of life
KW - outcomes
KW - scoliosis surgery
KW - upper instrumented vertebra
UR - http://www.scopus.com/inward/record.url?scp=85126831052&partnerID=8YFLogxK
U2 - 10.3171/2021.2.SPINE201938
DO - 10.3171/2021.2.SPINE201938
M3 - Article
C2 - 34450577
AN - SCOPUS:85126831052
SN - 1547-5654
VL - 35
SP - 761
EP - 773
JO - Journal of Neurosurgery: Spine
JF - Journal of Neurosurgery: Spine
IS - 6
ER -